In a population-based Swedish study, risk for cervical cancer was reduced by 88% among women who were immunized before age 17.
Human papillomavirus (HPV) vaccines were licensed based on their efficacy at reducing incidence of high-grade intraepithelial neoplasia, a precursor to cervical cancer; however, the public health goal in immunizing women is to prevent invasive cervical cancer. In a Swedish population-based study, researchers assessed incidence of cervical cancer in >1.6 million girls and women (age range, 10–30) who were followed from 2006 through 2017. Quadrivalent HPV vaccine was introduced in Sweden in 2007 for girls aged 13 to 17, with subsequent programs for catch-up (for girls through age 18) and initiation of immunization at age 10.
In this cohort, in which 32% of girls received at least 1 dose of HPV vaccine, 19 cases of cervical cancer were diagnose…
Reviewing Author
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)